Infliximab and Intravenous Gammaglobulin in Hospitalized Severe COVID-19 Patients in Intensive Care Unit

Background: Severe coronavirus disease 2019 (COVID-19) may lead to the cytokine storm syndrome which cause acute respiratory failure and death. Our aim was investigate therapeutic effects of infliximab, intravenous gammaglobulin (IVIg) or combination therapy in patients with severe COVID-19 admitted intensive care unit (ICU). Methods: In this observational research, we studied 104 intubated adult infection (based on clinical symptoms, radiographic CT scan parameters) who were ICU a multispecialty hospital during March 2020 Tehran, Iran. All cases received standard treatment regimens as local protocol (Oseltamivir + hydroxychloroquine lopinavir/ritonavir sofosbuvir atazanavir ± ribavirin). The grouped controls (n = 43), infliximab 27), IVIg 23) 11). Results: There no significant difference between groups terms underlying diseases number diseases. mean age (SD) 72.42 (16.06) control group, 64.52 (12.965) IVIg, 63.40 (17.57) 64.00 (11.679) therapy; ( P 0.047, 0.031 0.11, respectively). Also, 37% 26.1% 45.5% therapy, 62.8% group expired (all < 0.05). Hazard ratios 0.31 (95% CI: 0.12-0.76, 0.01), 0.30 0.13-0.67, 0.004), 0.39 0.12-1.09, 0.071). Conclusion: According findings study, it seems that alone together, can be considered an effective treatment.